A peri-operative Phase II study reported encouraging results for pembrolizumab combined with lenvatinib in mucosal melanoma, according to findings published in Nature Communications. The regimen targets both immune checkpoints and angiogenesis signaling in a cancer type where durable outcomes remain difficult. The trial was led by Mao, Lai, Zheng, and colleagues, with a focus on the peri-operative setting—an approach designed to prime and sustain systemic immune response around surgery. The publication highlighted signals consistent with clinically meaningful activity. The study adds evidence supporting combination strategies for mucosal melanoma and informs how surgeons and medical oncologists may sequence systemic therapy around resection.